{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:27Z","timestamp":1787113647489,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116888","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:42:20Z","timestamp":1781278940000},"page":"116888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9474","authenticated-orcid":false,"given":"Karim","family":"Fizazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0380-9465","authenticated-orcid":false,"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"David Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-141X","authenticated-orcid":false,"given":"Jeanny B.","family":"Aragon-Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-2096","authenticated-orcid":false,"given":"Martin","family":"Schostak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Tutrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-0888","authenticated-orcid":false,"given":"Daniel","family":"Sentana-Lledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-2507","authenticated-orcid":false,"given":"Heikki","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ateesha F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Littleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Buttkewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7419-5234","authenticated-orcid":false,"given":"Iris","family":"Kuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2026.116888_bib1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116888_bib2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2026.116888_bib3","unstructured":"National Cancer Institute. SEER*Explorer: An interactive website for SEER cancer statistics. Data sources: SEER Incidence Data, November 2024 Submission (1975-2022), SEER 8 registries, https:\/\/seer.cancer.gov\/statistics-network\/explorer\/; 2024 [accessed May 27, 2026]."},{"issue":"1","key":"10.1016\/j.ejca.2026.116888_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12894-024-01427-6","article-title":"Prostate cancer presentation and management in the Middle East","volume":"24","author":"Sayan","year":"2024","journal-title":"BMC Urol"},{"issue":"10437","key":"10.1016\/j.ejca.2026.116888_bib5","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2026.116888_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21147\/j.issn.1000-9604.2022.03.07","article-title":"National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)","volume":"34","author":"National Health Commission Of The People's Republic Of China","year":"2022","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2026.116888_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/bco2.116","article-title":"Mortality in men with castration-resistant prostate cancer: a long-term follow-up of a population-based real-world cohort","volume":"3","author":"Khoshkar","year":"2022","journal-title":"BJUI Compass"},{"issue":"1","key":"10.1016\/j.ejca.2026.116888_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40644-020-00333-y","article-title":"Does whole-body bone SPECT\/CT provide additional diagnostic information over [18F]-FCH PET\/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?","volume":"20","author":"de Leiris","year":"2020","journal-title":"Cancer Imaging"},{"issue":"3","key":"10.1016\/j.ejca.2026.116888_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/biology10030210","article-title":"Prevalence of prostate cancer at different clinical stages in Italy: estimated burden of disease based on a modelling study","volume":"10","author":"Spandonaro","year":"2021","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.ejca.2026.116888_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(18)30780-0","article-title":"Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study","volume":"20","author":"Downing","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116888_bib11","unstructured":"Ryll B., Mikhael J., Gutierrez Ibarluzea I., Morgan K., Ocokoljic M., Vassal G., et al. White Paper: Improving the understanding, acceptance and use of oncology-relevant endpoints in HTA body\/payer decision-making, https:\/\/www.efpia.eu\/media\/t2nlhr0k\/improving-the-understanding-acceptance-and-use-of-oncology-relevant-endpoints.pdf; 2023 [accessed May 27, 2026]."},{"issue":"8","key":"10.1016\/j.ejca.2026.116888_bib12","first-page":"6985","article-title":"Health-related quality of life of advanced prostate cancer patients and spouses: results from actor-partner interdependence models","volume":"30","author":"Sauer","year":"2022","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.116888_bib13","first-page":"324","article-title":"Disease-related complications in patients with metastatic hormone-sensitive prostate cancer","volume":"29","author":"Ng","year":"2023","journal-title":"Hong Kong Med J"},{"issue":"3","key":"10.1016\/j.ejca.2026.116888_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.clgc.2020.08.008","article-title":"Resetting the bar of castration resistance - understanding androgen dynamics in therapy resistance and treatment choice in prostate cancer","volume":"19","author":"Shore","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2026.116888_bib15","first-page":"684","article-title":"Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States","volume":"30","author":"Kaye","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ejca.2026.116888_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240864","article-title":"Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews","volume":"13","author":"Leaning","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116888_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41391-022-00529-2","article-title":"Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study","volume":"26","author":"Roy","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.ejca.2026.116888_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.34018","article-title":"Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)","volume":"151","author":"James","year":"2022","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.116888_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116888_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2026.116888_bib21","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2026.116888_bib22","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2026.116888_bib23","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10336","key":"10.1016\/j.ejca.2026.116888_bib24","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2026.116888_bib25","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116888_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ejca.2026.116888_bib27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug\u2013drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116888_bib28","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug\u2013drug interaction potential of darolutamide: in vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.ejca.2026.116888_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","article-title":"Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial","volume":"18","author":"Williams","year":"2023","journal-title":"Target Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116888_bib30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","article-title":"Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): An open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116888_bib31","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116888_bib32","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116888_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1526-4637.2009.00774.x","article-title":"The Brief Pain Inventory and its \"pain at its worst in the last 24\u2009h\" item: clinical trial endpoint considerations","volume":"11","author":"Atkinson","year":"2010","journal-title":"Pain Med"},{"issue":"9","key":"10.1016\/j.ejca.2026.116888_bib34","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/pon.1817","article-title":"Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN\/FACT-P Symptom Index","volume":"20","author":"Victorson","year":"2011","journal-title":"Psycho-Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.116888_bib35","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/cncr.31973","article-title":"Meaningful differences and validity for the NCCN\/FACT-P Symptom Index: an analysis of the ALSYMPCA data","volume":"125","author":"Beaumont","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116888_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euros.2023.03.001","article-title":"Patient and general population preferences regarding the benefits and harms of treatment for metastatic prostate cancer: a discrete choice experiment","volume":"51","author":"Menges","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ejca.2026.116888_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.euros.2021.10.003","article-title":"A systematic review of patients' values, preferences, and expectations for the treatment of metastatic prostate cancer","volume":"36","author":"Connor","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.ejca.2026.116888_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euo.2024.04.010","article-title":"Patient-reported quality of life and survival outcomes in prostate cancer: analysis of the ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED)","volume":"8","author":"Sentana-Lledo","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116888_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/2767-9764.CRC-23-0446","article-title":"Pain and its association with survival for Black and White individuals with advanced prostate cancer in the United States","volume":"4","author":"Rencsok","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"2","key":"10.1016\/j.ejca.2026.116888_bib40","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/j.clgc.2017.09.015","article-title":"Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey","volume":"16","author":"Drudge-Coates","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2026.116888_bib41","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116888_bib42","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/JU.0000000000001841","article-title":"Apalutamide plus androgen deprivation therapy for metastatic castration-sensitive prostate cancer: analysis of pain and fatigue in the phase 3 TITAN study","volume":"206","author":"Agarwal","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116888_bib43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"issue":"13","key":"10.1016\/j.ejca.2026.116888_bib44","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/pros.24396","article-title":"The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups","volume":"82","author":"Stenzl","year":"2022","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.ejca.2026.116888_bib45","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.21.00941","article-title":"Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP","volume":"40","author":"Stockler","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116888_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","article-title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"103","author":"Feyerabend","year":"2018","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.116888_bib47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial","volume":"40","author":"Rush","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116888_bib48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116888_bib49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41391-023-00668-0","article-title":"Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy","volume":"27","author":"Afferi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10467","key":"10.1016\/j.ejca.2026.116888_bib50","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2026.116888_bib51","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment","volume":"5","author":"Menges","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116888_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:15:15Z","timestamp":1787112915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"alternative-id":["S0959804926006696"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116888","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116888"}}